Every one of those 1 sits in a single category, pharma. Eric Wintemute is most often covered alongside American Vanguard, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Eric Wintemute
Every one of those 1 sits in a single category, pharma. Eric Wintemute is most often covered alongside American Vanguard, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window. Source depth averages 3 original sources per story, versus 3.3 across the same-window beat baseline. Eric Wintemute appears in 1 tracked Biotech story from March 17, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Eric Wintemute. Shared-story counts are live from our verified record — not editorial picks.
American Vanguard (NYSE: AVD) reported its full-year 2025 financial results, highlighting a return to growth following a period of strategic restructuring and inventory destocking in the global agricultural sector. The company emphasized the expansion of its 'Green Solutions' biological portfolio and the successful implementation of its business transformation initiative.
Eric Wintemute is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.